Background: The gut microbiome, which consists of a highly diverse ecologic community of microorganisms, has increasingly been studied regarding its role in multiple sclerosis (MS) immunopathogenesis. This review critically examines the literature investigating the gut microbiome in MS. Methods: A comprehensive search was performed of PubMed databases and ECTRIMS meeting abstracts for literature relating to the gut microbiome in MS. Controlled studies examining the gut microbiome in patients with MS were included for review. Results: Identified studies were predominantly case-control in their design and consistently found differences in the gut microbiome of MS patients compared to controls. We examine plausible mechanistic links between these differences and MS immunopathogenesis, and discuss the therapeutic implications of these findings. Conclusions: Review of the available literature reveals potential immunopathogenic links between the gut microbiome and MS, identifies avenues for therapeutic advancement, and emphasizes the need for further systematic study in this emerging field.
Introduction
The gut microbiota has emerged as an area of intense interest in multiple sclerosis (MS). Composed of approximately 10 14 highly diverse micro-organisms, the gut microbiota is vital to digestion and metabolism. 1 Its immunologic functions, however, including physical blockade of ingested potential pathogens, oral tolerization to antigenic stimuli, and modulation of the gut-associated lymphoid tissue (GALT) may play a significant role in autoimmune diseases such as MS. [1] [2] [3] Research examining the gut microbiota in MS is framed by our understanding of MS immunopathogenesis. Infiltration of Th1 and Th17 CD4+ T-cells into the central nervous system seems to be prominent in MS. 4 CD4+ T-regulatory cells protect against autoimmunity by suppressing auto-reactive effector T-cells, and decreased numbers or defective function of T-regulatory cells may also contribute to the development of MS. 4 Environmental factors such as the gut microbiota may contribute to MS immunopathogenesis by directing differentiation of CD4+ T-cell phenotypes or impacting T-regulatory cell function. Previously reviewed animal studies have demonstrated that alteration of the gut microbiota can powerfully modulate immune-mediated demyelination in experimental autoimmune encephalomyelitis (EAE) and paved the way for examination of the gut microbiota in MS. 2, 5 The gut microbiome in MS Imbalance, or "dysbiosis" of the gut microbiota, is implicated in numerous diseases, including obesity, diabetes mellitus type 2 (T2DM), diabetes mellitus type 1 (T1DM), inflammatory bowel disease (IBD), and rheumatoid arthritis (RA). 3 Examination of the gut microbiota in MS requires a working understanding of normal human gut microbiota composition. Over 99% of the gut microbiota genome, also known as the "microbiome," is bacterial, with most bacteria in the adult human gut belonging to the Firmicutes or Bacteroidetes phyla. 1 The remaining genes are largely from Archaea, a separate prokaryote kingdom. 1 The advent of massive parallel sequencing technology, such as 16S rRNA sequencing, has led to the genetic profiling of gut microbiota that previously were unidentifiable through traditional culture techniques; this has hugely advanced our ability to study the gut microbiome composition in diseases such as MS. 1, 3 Unlike Clostridium difficile infection, large shifts in gut microbial community composition have generally not been observed in MS. Instead, enrichment or depletion of a limited number of taxa seems to be a reproducible finding. 6, 7 We systematically review alterations in the gut microbiota that have been identified in patients with MS (see Table 1 ) and discuss their potential contributions to MS pathogenesis (see Table 2 ).
Firmicutes and butyrate production
The majority of bacteria in the adult human gut belong to the phylum Firmicutes. 1, 3 An early study of the gut microbiome in MS by Rumah et al. 16 implicated epsilon toxin (ETX)-producing Clostridium perfringens, which belongs to the Firmicutes phylum, in MS pathogenesis. The authors isolated ETX-producing Clostridium perfringens Type B from the stool of an MS patient and found that 10% of their MS patients had ETX-specific antibodies compared to only 1% of controls, indicating increased immune system exposure to ETX. 16 This toxin can disrupt the blood-brain barrier and bind myelin, leading to its consideration as a potential MS trigger. 16 Although provocative, further study is needed to explore any possible pathogenic role of ETX-producing Clostridium perfringens in MS.
Human bacterial colonic producers of the short-chain fatty acid (SCFA) butyrate have garnered interest for their immunomodulatory effects and are also largely Firmicutes, most abundantly Faecalibacterium prausnitzii and Eubacterium rectale/Roseburia spp. 17, 18 Butyrate inhibits the pro-inflammatory signaling pathway nuclear factor-kappa B (NFkB) in colonic epithelial cells and prevents systemic exposure to dietary or microbial antigenic stimuli via intestinal epithelial cell barrier reinforcement. 17, 18 As such, depletion of butyrate-producing Firmicutes may plausibly be linked to the pathogenesis of immunemediated diseases such as MS. In support of this hypothesis, a pilot study of the gut microbiome in MS by Cantarel et al. 14 Jangi et al. 7 identified a reduction in Butyricimonas among 60 RRMS patients, which belongs to the Bacteroidetes phylum but is capable of producing butyrate as well. Butyricimonas was similarly depleted in pediatric patients with early MS. 6 In another pediatric study, Tremlett et al. 12 followed 17 early MS patients over a mean of 19.8 months and found that absence of the Fusobacteria phylum, which also contains butyrate-producing species, was associated with shorter time to relapse. 35 Presence of Fusobacteria, however, has been associated with autoimmune diseases such as juvenile idiopathic arthritis, and further research is therefore required to better delineate its potential role in MS. 36 Nonetheless, the reproducibly identified depletion of butyrate-producing bacteria in MS may be a pro-inflammatory gut microbial alteration with significant contribution to disease immunopathogenesis.
Bacteroidetes
Bacteroidetes are the second most populous phylum in the adult human gut, with the predominant genera being Bacteroides and Prevotella. 37 Miyake et al. 13 found reductions in Bacteroidetes, including several Bacteroides species and Prevotella copri, among their RRMS patients. Chen et al. 11 similarly found depletion of Prevotella among their patients with RRMS, and Castillo Alvarez et al. 8 also reported a reduced abundance of Prevotella copri among MS patients that seemed to partially normalize with IFN-beta treatment. Baum et al. 15 identified reduced Bacteroidaceae among 54 MS patients, a finding also noted by Tremlett et al. 6 among patients with pediatric early MS.
Across studies, depletion of Bacteroidetes seems to be a repeatedly identified alteration in the gut microbiome of patients with MS. This may relate to Lipid 654, a bacterially derived lipodipeptide that is produced by a number of Bacteroidetes and was found to have lower serum levels among MS patients compared to controls. 13, 19 Lipid 654 binds toll-like receptor 2 (TLR2); although TLRs are critical to innate immune system activation, low-level tonic TLR2 stimulation by Lipid 654 has been shown to regulate innate immune responses. 19, 20 Tremlett et al. 10 Case-control 15 pediatric early RRMS patients (2 IFNbeta-treated, 5 glatiramer acetate (GA)treated, 8 untreated) versus 9 controls. In this exploratory study looking at associations between the gut microbiota and immune markers, no difference in immune markers between cases and controls was found. However, several associations between immune markers and certain gut microbiota, including Bacteroidetes and Actinobacteria, were noted.
Jangi et al. 7 Case-control 60 RRMS patients ( Baum et al. 15 Case-control 54 MS patients versus controls (number of controls not stated in abstract). Increased Atopobium, increased Bifidobacterium, and decreased Bacteroidaceae was found in MS patients compared to controls.
Rumah et al. 16 Case-control 30 MS patients (26 RRMS, 4 secondary progressive multiple sclerosis (SPMS)) versus 31 controls Epsilon toxin (ETX)-producing Clostridium perfringens Type B was isolated from an MS patient.
Non-ETX-producing Clostridium perfringens Type A was found in 52% of controls compared to only 23% of MS patients. ETX-specific antibodies were found in 10% of MS patients compared to only 1% of controls. Mostly Firmicutes, some Bacteroidetes, some Fusobacteria Decreased butyrate-mediated inhibition of pro-inflammatory NFkB signaling pathway and prevention of systemic exposure to gut antigenic stimuli may be implicated in MS pathogenesis. 17, 18 Bacteroides, Prevotella, and Parabacteroides Bacteroidetes Lipid 654 produced by some Bacteroidetes may tonically stimulate toll-like receptor (TLR)-2, leading to innate immune regulation that is lost when Bacteroidetes is depleted. 19, 20 Propionate is a short-chain fatty acid (SCFA) with antiinflammatory effects that is produced by some Bacteroidetes, and reduced propionate-producing Bacteroidetes may promote inflammation. [21] [22] [23] Bacteroides fragilis-derived polysaccharide A (PSA) may induce IL-10-dependent enhanced conversion of CD4+ T-regulatory cells and protect against autoimmunity in MS. 24, 25 Oral administration of Parabacteroides distasonis may augment the CD4+ T-regulatory phenotype, plausibly linking its depletion in MS pathogenesis. 9
Increased abundance in multiple sclerosis
Epsilon-toxin (ETX)-producing Clostridium perfringens Firmicutes ETX has been shown to disrupt the blood brain barrier and bind myelin. 16 Increased exposure to ETX produced by Clostridium perfringens Types B and/or D may therefore play a role in triggering demyelination in MS.
Methanobrevibacter Euryarchaeota
Methanogenic archaea may cause human dendritic cell activation and triggering of adaptive immune responses, suggesting a pro-inflammatory effect. 7, 26, 27 Further study of Methanobrevibacter in MS is needed, with adjustment for potential confounding effect of the positive association between constipation and methanogenic archaea.
Bilophila, Pseudomonas, Mycoplana, and Acinetobacter
Proteobacteria Proteobacteria have been associated with IBD by driving inflammation and promoting gut dysbiosis, suggesting a pro-inflammatory effect that may also contribute to MS pathogenesis. 28 A shared molecular sequence between Acinetobacter calcoaceticus and an encephalitogenic peptide of bovine myelin, as well as elevated anti-Acinetobacter antibodies in MS patients compared to controls, suggests a potential role in MS pathogenesis via molecular mimicry. 29 Acinetobacter calcoaceticus may also reduce T-regulatory cell function in MS. 9
Akkermansia Verrucomicrobia
Reduced Akkermansia muciniphila was noted in IBD, but this bacterium has also been found to facilitate Salmonella infection in a mouse model; 30, 31 potential link to MS unclear but may relate to promotion of a pro-inflammatory T-cell phenotype. 9
Bifidobacterium Actinobacteria
Increased Bifidobacterium associated with IBD, 32 but administration of some Bifidobacterium spp. and other probiotic bacteria associated with EAE amelioration; 33, 34 how increased Bifidobacterium identified in some studies of the gut microbiome in MS relates to disease activity is unclear.
Decreased Lipid 654-producing Bacteroidetes may therefore lead to a loss of innate immune regulation and in turn enable the immune auto-reactivity seen in MS. 19 Bacteroidetes also produce propionate, a SCFA similar to butyrate that has anti-inflammatory effects. [21] [22] [23] Oral propionate administration has been shown to increase T-regulatory cells and decrease Th1/Th17 cells in patients with MS, supporting the possibility that depletion of propionate-producing Bacteroidetes may play a role in MS pathogenesis. 23 Cekanaviciute et al. 9 found that one particular Bacteroidetes species, Parabacteroides distasonis, was decreased among 64 MS patients compared to controls. Parabacteroides distasonis may augment the CD4+ T-regulatory cell phenotype, plausibly linking its depletion to MS immunopathogenesis. 9 Tremlett et al. 6 identified a reduction in another Bacteroidetes species, Bacteroides fragilis, among their pediatric early MS cases. Bacteroides fragilisderived polysaccharide A (PSA) has been shown to induce T-regulatory cells in vitro and protect against EAE in vivo. 24, 25 Bacteroides fragilis PSA uniquely exemplifies a single gut microbial-derived product that demonstrates anti-inflammatory properties and seems protective against immune-mediated demyelination, suggesting therapeutic potential in MS.
Euryarchaeota
The Euryarchaeota phylum belongs to the prokaryotic kingdom Archaea, with the predominant colonic species being methane-producing Methanobrevibacter smithii. 26 Euryarchaeota have been implicated in inflammatory processes; Methanosphaera stadtmanae is increased in IBD, while both Methanosphaera stadtmanae and Methanobrevibacter smithii can cause human dendritic cell activation. 27, 38 Interestingly, Jangi et al. 7 found increased Methanobrevibacter among 60 RRMS patients compared to controls. Tremlett et al. 6 similarly found enrichment of Methanobrevibacter among their patients with pediatric early MS. Castillo Alvarez et al., 8 however, found a lower abundance of Archaea among 30 MS patients compared to controls, suggesting that further investigation of the relationship between Methanobrevibacter and MS is warranted. Importantly, the association between constipation and increased methanogenic archaea is a potential confounder that should be controlled for in future studies, given the high prevalence of constipation in MS. 7, 26 Other microorganisms Several other differences in the gut microbiome of MS patients have been identified. Chen et al. 11 found an increased abundance of Pseudomonas and Mycoplana, which belong to the phylum Proteobacteria, among their patients with RRMS. Additionally, Tremlett et al. 6 identified increased Bilophila among patients with pediatric early MS, which also belongs to Proteobacteria. Proteobacteria have been associated with IBD by driving inflammation and promoting gut dysbiosis, which may contribute to the development of other autoimmune diseases such as MS. 28 Cekanaviciute et al. 9 found that MS patients had increased Acinetobacter calcoaceticus, a bacteria also belonging to Proteobacteria. Molecular database analysis has identified a shared sequence between Acinetobacter calcoaceticus and an encephalitogenic peptide of bovine myelin, while elevated anti-Acinetobacter antibodies have been found in MS patients compared to controls; these findings support molecular mimicry as a potential immunopathogenic link between Acinetobacter and MS. 29 Cekanaviciute et al. 9 demonstrated a reduction in CD4+ T-regulatory cell differentiation after in vitro T-cell stimulation with Acinetobacter calcoaceticus, suggesting this bacteria may also promote autoimmunity by impairing T-regulatory cell function.
Jangi et al. 7 found increased Akkermansia among RRMS patients, which belongs to the phylum Verrucomicrobia. Cekanaviciute et al. 9 also noted increased Akkermansia muciniphila among their MS patients. Akkermansia muciniphila, a mucin-degrading bacteria, has been found to facilitate infection and inflammation by Salmonella typhimurium in mice; 30 reduced Akkermansia muciniphila, however, has been observed in IBD. 31 The implications of increased Akkermansia in MS are therefore unclear. Cekanaviciute et al. found that Akkermansia muciniphila promotes Th1 cell expansion in vitro, and Jangi et al. 7 demonstrated that increased Akkermansia and Methanobrevibacter both positively correlate with the expression of pro-inflammatory T-cell and monocyte genes implicated in MS pathogenesis. 9 In contrast, Butyricimonas inversely correlates with these genes, suggesting that gut microbiota may contribute to MS pathogenesis by polarizing toward an inflammatory rather than immunomodulatory T-cell phenotype. 7 Baum et al. 15 noted increased Bifidobacterium among MS patients, which belong to the phylum Actinobacteria. Tremlett et al. 6 similarly found an increase in Bifidobacterium among pediatric patients with early MS. Increased Bifidobacterium, which is commonly administered as probiotic therapy, has also been linked to IBD. 32 However, Bifidobacterium animalis and a probiotic mixture including Bifidobacterium bifidum significantly ameliorated EAE activity, with evidence of inhibited Th1/Th17 cell polarization and T-regulatory cell induction. 33, 34 The reason for this conflicting data regarding Bifidobacterium in immunemediated demyelinating disease is unclear; further study into the potential role of Bifidobacterium and other probiotic therapy in MS is needed.
Therapeutic considerations

Diet
Emerging evidence has found that numerous diseasemodifying therapies (DMTs) affect gut microbiota composition; 7, 10, 14, 39 no therapy, however, has been developed with the intent of beneficially altering the gut microbiota in MS. Understanding pathogenic links between the gut microbiota and MS therefore creates opportunities for therapeutic innovation. Dietary change rapidly alters the gut microbiota and is one treatment consideration. 40 Some Firmicutes that produce the SCFA butyrate are increased among patients assigned to a plant-based rather than animal-based diet, and SCFAs may have a beneficial anti-inflammatory effect in MS. 22, 23, 40 Probiotic bacteria have been shown to improve EAE; 33, 34 whether there is any benefit to dietary probiotic supplementation in MS, however, is unknown, and caution may even be warranted given increased Bifidobacterium identified in some MS gut microbiome studies. 6, 15 Dietary modifications that might favorably alter the gut microbiota in MS, such as a plant-based diet, SCFA supplementation or probiotic administration, require further evaluation. At a minimum, diet is a potential confounder that needs to be considered when studying the gut microbiome in MS.
Helminth therapy
Parasitic infestation has theoretical benefit in MS by skewing from a Th1 to Th2 cell phenotype and increasing T-regulatory cells to facilitate helminth tolerance. 41 This is supported epidemiologically by a strong inverse relationship between MS and Trichuris trichiura prevalence. 42 Correale and Farez 41 also found a dramatic 95% relative reduction in relapses and Gadolinium (Gd)-enhancing lesions among 12 community-acquired helminth-infested MS patients compared to uninfested controls, with evidence of associated T-regulatory cell induction. Unfortunately, the HINT 2 (Helminth-induced Immunomodulatory Therapy) trial found only a modest 34% relative reduction in Gd-enhancing lesions among 15 RRMS patients treated orally with Trichuris suis ova (TSO), and an open-label therapeutic trial of TSO oral therapy in 10 RRMS patients found no benefit. 43, 44 The reason for the more robust positive effect of naturally-acquired helminth infestation compared to clinical trials of helminth therapy in MS is unclear and could relate to the gut microbiota. Previously reviewed literature has found abundant evidence of helminth-gut microbiota interactions. 45 It is intriguing that in the prospective observational study by Correale and Farez, 46 helminthuninfested MS patients remained uninfested over 90 months of follow-up despite living in areas with high prevalence of helminth infection. Communityacquired helminth infestation may naturally select for individuals with gut microbiota that favorably influence both establishment of infestation and helminthmediated immunomodulation, explaining the more impressive therapeutic effect of naturally occurring helminth infestation in MS. Examination of the gut microbiome in larger-scale helminth trials may shed light on the therapeutic mechanisms of helminth therapy in MS.
Fecal microbiota transplantation
Fecal microbiota transplantation (FMT) is used to treat patients with recurrent Clostridium difficile infection, an antibiotic-associated bacterial colitis that may be life-threatening. 47 Antimicrobial therapy disrupts normal intestinal microflora and facilitates Clostridium difficile infection; transplantation of healthy donor stool is believed to restore fecal microbial diversity in the recipient and prevent Clostridium difficile recurrence. 47 As evidence of gut dysbiosis in MS mounts, FMT from donors free of autoimmune disease may be a consideration to restore gut microbial balance. The depletion of butyrate-producing bacteria observed in MS is also seen in Clostridium difficile infection and is replenished after FMT; this anti-inflammatory alteration to the gut microbiota after FMT lends biologic plausibility to a potential therapeutic role for FMT in MS. 48 Interestingly, Borody et al. 49 reported neurologic benefit in three MS patients who underwent FMT for constipation. The neurologic improvement was dramatic, including recovery of bowel and bladder function and regained ability to walk. Although enthusiasm for these findings is tempered by the absence of controls, the diagnosis of "atypical" MS in two patients, and the unclear mechanisms behind how FMT could reverse established MS disease burden, further investigation of FMT in MS seems warranted. 49
Conclusion and future directions
The gut microbiome is a new and exciting frontier in MS research. There is growing evidence demonstrating alterations in the gut microbiota of patients with MS, and plausible immunologic links between these differences and MS pathogenesis. A better understanding of this field also facilitates the development of gut-directed treatments in MS, such as dietary modification, helminth therapy, Bacteroides fragilisderived PSA and even FMT. Current observational studies reproducibly demonstrate gut dysbiosis in MS but are limited by their small size and cross-sectional nature, which is likely the reason for differing and occasionally conflicting results. Larger-scale, longitudinal, multicentre endeavors such as the International MS Microbiome Study will likely provide valuable insights, and allow for stratification of potential confounders such as age, sex, weight, ethnicity, geographic location, diet, disease phenotype and use of DMTs. 50 Effective interpretation of future gut microbiome research will be critical to uncovering immunopathogenic mechanisms and advancing therapeutic possibilities in MS.
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